Accéder au contenu principal

hfpef-diva

Publications

Publications emanating from HFpEF-DIVA

  • Clonal Hematopoiesis and Inflammatory Pathways in Heart Failure with Preserved Ejection Fraction. Eline Verghote, Vanessa P M van Empel, Job A J Verdonschot Curr Heart Fail Rep. 2026 ;23(1):47. doi: 10.1007/s11897-026-00779-4.
  • Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets. Ellaline Cami, Eline Verghote, Emily Pecetto, Arantxa González, Ebba Brakenhielm, Elizabeth Av Jones, Vanessa Van Empel Curr Heart Fail Rep 2026 ;23(1):36. doi: 10.1007/s11897-026-00745-0
  • Heart failure with a preserved ejection fraction: synergy between cardiac and extracardiac mechanisms and effects of novel therapies. Soufiane Nassiri, M Louis Handoko, Arno A van de Bovenkamp, Vanessa P M van Empel, Daniël H van Raalte, Etto C Eringa. Heart Fail Rev. 2026 ;31(1):108. doi: 10.1007/s10741-026-10671-x.
  • Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics. Susana Ravassa, Nicolas Girerd, Frank Edelman, Begoña López, João Pedro Ferreira, Daniela Zurkan, Gorka San José, Iñigo Latasa, Pierpaolo Pellicori, Franco Cosmi, Johannes Petutschnigg, Stephane Heymans, Hans-Peter Brunner-La Rocca, Burkert Pieske, Christian Delles, Andrew L Clark, Javier Díez, Faiez Zannad, John G F Cleland, Arantxa González; HOMAGE Trial Committees and Investigators MedComm. 2026 ;7(3):e70634. doi: 10.1002/mco2.70634.
  • Circulating collagen type I fragments as specific biomarkers of cardiovascular outcome risk: Where are the opportunities? Emily M Martin, Joan Chang, Arantxa González, Federica Genovese. Matrix Biol. 2025:137:19-32. doi: 10.1016/j.matbio.2025.03.001
  • How to facilitate seamless translation from basic concepts to new heart failure drugs. A scientific statement of the Heart Failure Association of the ESC. Carlo Gabriele Tocchetti , Arantxa González , Johannes Backs, Piero Pollesello, Peter P Rainer, Gabriele Giacomo Schiattarella, Milena Bellin, Glenn Begley, Ildiko Bock Marquette, Jean-Luc Balligand, Ines Falcao-Pires, Rick Gorczynski, Emilio Hirsch, Jean-Sebastian Hulot, Bert Klebl, Alexander R Lyon, Christoph Maack , Timothy A McKinsey, Oliver J Müller, Ida Lunde, Rusty Montgomery, Giuseppe Vergaro, Antoni Bayes-Genis, Thomas Thum, Peter van der Meer, Linda Van Laake, Franck Ruschitzka, Petar Seferovic, Andrew J Coats, Marco Metra, Giuseppe Rosano, Sophie Van Linthout, Rudolf A de Boer Eur J Heart Fail. 2025;27(8):1379-1392. doi: 10.1002/ejhf.3709
  • Targeted proteomic profiling of transcatheter edge-to-edge repair failure in patients with mitral regurgitation and heart failure. Mattia Di Pasquale, Susana Ravassa, Matteo Pagnesi, Edoardo Pancaldi, Begoña López, Gorka San José, Cristina Gussago, Letizia Fiorentino, Alice Ravera, Lisa Serafini, Giuliano Chizzola, Carlo Mario Lombardi, Marco Metra, Arantxa González, Marianna Adamo. Clin Res Cardiol. 2025. doi: 10.1007/s00392-025-02712-6
  • Circulating biomarkers of myocardial remodelling: current developments and clinical applications. Begoña López, Susana Ravassa, Gorka San José, Iñigo Latasa, Blanca Losada-Fuentenebro, Leire Tapia, Javier Díez , Antoni Bayés-Genís, Arantxa González. Heart. 2024 ;110(19):1157-1163. doi: 10.1136/heartjnl-2024-323865
  • Myocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact. Ida G Lunde, Karoline B Rypdal, Sophie Van Linthout, Javier Diez, Arantxa González. Matrix Biol. 2024 :134:1-22. doi: 10.1016/j.matbio.2024.08.008

Previous relevant publications from HFpEF-DIVA team members

  • Modulating Effect of Carbohydrate Antigen 125 on the Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure. Santas E, Martí-Martínez A, Revuelta-López E, Villar S, de la Espriella R, Palau P, Llàcer P, Miñana G, Rodriguez-Borja E, Carratalá A, Gonzalez A, Bayés-Genís A, Sanchis J, Núñez J. Biomolecules. 2025 ;15(9):1260. doi: 10.3390/biom15091260
  • Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Adamo M, Pagnesi M, Chioncel O, Bayes-Genis A, Abdelhamid M, Antohi EL, Bucciarelli-Ducci C, Chieffo A, Cosyns B, Gilard M, Grapsa J, González A, Gustafsson F, Iung B, Joner M, Karam N, Lund LH, Maisano F, Moura B, Praz F, Rudolph TK, Sannino A, Savarese G, Tocchetti CG, Van Empel VPM, Volterrani M, Windecker S, Ponikowski P, Rosano GMC, Barbato E, Metra M.
    Eur J Heart Fail. 2025 doi: 10.1002/ejhf.70023.
  • CCR2(+) monocyte-derived macrophages drive cardiac hypertrophy in early HFpEF. Jana Raman, Steven Simmonds, Ellen Caluwé, Rick van Leeuwen, Caroline Walschap, Mathias Stroobants, Ümare Cöl, Petra Vandervoort, Stephane Heymans, Elizabeth A V Jones. Am J Physiol Heart Circ Physiol. 2025 ;329(1):H109-H123. doi: 10.1152/ajpheart.00022.2025
  • Metabolic and Immune Crosstalk in Cardiovascular Disease. Mohanta SK, Heron C, Klaus-Bergmann A, Horstmann H, Brakenhielm E, Giannarelli C, Habenicht AJR, Gerhardt H, Weber C. Circ Res. 2025 ;136(11):1433-1453. doi: 10.1161/CIRCRESAHA.125.325496.
  • The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction. Mourmans SGJ, Achten A, Hermans R, Scheepers MJE, D'Alessandro E, Swennen G, Woudstra J, Appelman Y, Goor HV, Schalkwijk C, Knackstedt C, Weerts J, Eringa EC, van Empel VPM. Cardiovasc Diabetol. 2025 ;24(1):182. doi: 10.1186/s12933-025-02679-8.
  • Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling. Grootaert MOJ, Pasut A, Raman J, Simmonds SJ, Callewaert B, Col Ü, Dewerchin M, Carmeliet P, Heymans S, Jones EAV. Cardiovasc Diabetol. 2025 ;24(1):62. doi: 10.1186/s12933-025-02623-w
  • Pericyte loss initiates microvascular dysfunction in the development of diastolic dysfunction. Simmonds SJ, Grootaert MOJ, Cuijpers I, Carai P, Geuens N, Herwig M, Baatsen P, Hamdani N, Luttun A, Heymans S, Jones EAV. Eur Heart J Open. 2023 ;4(1):oead129. doi: 10.1093/ehjopen/oead129
  • Improving insights into the heterogeneous HFpEF syndrome through microvascular research. Weerts J, Mourmans SGJ, Eringa E, van Empel VPM. J Mol Cell Cardiol. 2022;167:106-108. doi: 10.1016/j.yjmcc.2022.04.001
  • The HFA-PEFF score identifies 'early-HFpEF' phenogroups associated with distinct biomarker profiles. Henkens MTHM, van Ommen AM, Remmelzwaal S, Valstar GB, Wang P, Verdonschot JAJ, Hazebroek MR, Hofstra L, van Empel VPM, Beulens JWJ, den Ruijter HM, Heymans SRB. ESC Heart Fail. 2022;9(3):2032-2036. doi: 10.1002/ehf2.13861.
  • Impact analysis of heart failure across European countries: an ESC-HFA position paper. Rosano GMC, Seferovic P, Savarese G, Spoletini I, Lopatin Y, Gustafsson F, Bayes-Genis A, Jaarsma T, Abdelhamid M, Miqueo AG, Piepoli M, Tocchetti CG, Ristić AD, Jankowska E, Moura B, Hill L, Filippatos G, Metra M, Milicic D, Thum T, Chioncel O, Ben Gal T, Lund LH, Farmakis D, Mullens W, Adamopoulos S, Bohm M, Norhammar A, Bollmann A, Banerjee A, Maggioni AP, Voors A, Solal AC, Coats AJS. ESC Heart Fail. 2022 ;9(5):2767-2778. doi: 10.1002/ehf2.14076.
  • Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Cuijpers I, Simmonds SJ, van Bilsen M, Czarnowska E, González Miqueo A, Heymans S, Kuhn AR, Mulder P, Ratajska A, Jones EAV, Brakenhielm E. Basic Res Cardiol. 2020 ;115(4):39. doi: 10.1007/s00395-020-0798-y.